Illumina Inc. Keeps Up Its Winning Ways Thanks to NovaSeq Sales Growth
There was plenty to like when Illumina (NASDAQ: ILMN) reported its second-quarter results in August. Pretty much everything that could go right has gone right for the gene-sequencing leader. Illumina's stock performance so far in 2017 has reflected the good news for the company.
The streak of good news was at risk, however, when Illumina provided an update on its third-quarter performance after the market closed on Tuesday. Any concerns that investors had were alleviated, though: Illumina yet again delivered a strong quarter. Here are the highlights.
Image source: Getty Images.
Source: Fool.com
Illumina Inc. Stock
With 33 Buy predictions and 4 Sell predictions Illumina Inc. is one of the favorites of our community.
With a target price of 161 € there is a positive potential of 35.39% for Illumina Inc. compared to the current price of 118.92 €.